ArticleAnnals of nuclear medicine2021
Pretreatment
Article in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Tumor metabolic heterogeneity based onBMC cancer · 2025Article
- Association analysis of intratumoral metabolic heterogeneity assessed by the hottest lesion based onQuantitative imaging in medicine and surgery · 2025Article
- PretreatmentCancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Four-dimensional quantitative analysis using FDG-PET in clinical oncology.Japanese journal of radiology · 2023Review
- Prognostic value of pre-treatment FDG PET/CT SUVmax for metastatic lesions in de novo metastatic nasopharyngeal carcinoma following chemotherapy and locoregional radiotherapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- PET/CT standardized uptake value and EGFR expression predicts treatment failure in nasopharyngeal carcinoma.Radiation oncology (London, England) · 2023Article
- Particle beam therapy for nasopharyngeal cancer: A systematic review and meta-analysis.Clinical and translational radiation oncology · 2022Review
- Reflecting on the utility of standardized uptake values onBMC cancer · 2022Article
- The role of PET/CT in radiotherapy for nasopharyngeal carcinoma.Frontiers in oncology · 2022Review
- Prognostic Relevance of 18F-FDG-PET/CT-Guided Target Volume Delineation in Loco-Regionally Advanced Nasopharyngeal Carcinomas: A Comparative Study.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveOur study was to investigate the value of pretreatment
methodsTwenty-nine LRNPC patients who underwent whole-body
resultsIn this study, univariate analysis showed that HI was a significant predictor of LRNPC treated by CIRT. HI could be used to predict LRFS and PFS. Patients with HI (≥ 0.81) had a significantly worse prognosis of LRFS (12.25 vs. NR, p = 0.008), and of PFS (10.58 vs. NR, p = 0.014). The AUC and its sensitivity and sensitivity and specificity were 0.75, 84.21% and 70.00% for LRFS and 0.82, 80.95% and 75.00% for PFS, respectively. Multivariate analysis showed that HI was an independent predictor for the LFRS of LRNPC with CIRT.
conclusion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.